← back to search

Ravina Kullar

Twitter (United States) · US
Area of research
Infectious Diseases · Applied Microbiology and Biotechnology
Research interest
Research interests include Medicine, Daptomycin, Bacteremia, Staphylococcus aureus, Vancomycin, and Methicillin-resistant Staphylococcus aureus.
h-index
citations
1,152
works
13
NIH funding
primary concept
email

Recent publications

Recommendations to Improve Quality of Probiotic Systematic Reviews With Meta-Analyses
JAMA Network Open 2023cited by 20position: middledoi
Overcoming <i>Stenotrophomonas maltophilia</i> Resistance for a More Rational Therapeutic Approach
Open Forum Infectious Diseases 2022cited by 34position: firstdoi
Randomized Prospective Open Label Study Shows No Impact on Clinical Outcome of Adding Losartan to Hospitalized COVID-19 Patients with Mild Hypoxemia
Infectious Diseases and Therapy 2021cited by 30position: middledoi
Intravenous Immunoglobulin Plus Methylprednisolone Mitigate Respiratory Morbidity in Coronavirus Disease 2019
Critical Care Explorations 2020cited by 50position: middledoi
Clinical Data on Daptomycin plus Ceftaroline versus Standard of Care Monotherapy in the Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia
Antimicrobial Agents and Chemotherapy 2019cited by 188position: middledoi
Multicenter Cohort of Patients With Methicillin-Resistant Staphylococcus aureus Bacteremia Receiving Daptomycin Plus Ceftaroline Compared With Other MRSA Treatments
Open Forum Infectious Diseases 2019cited by 87position: middledoi
Going for the Gold: A Description of the Centers of Excellence Designation by the Infectious Diseases Society of America
Clinical Infectious Diseases 2018cited by 12position: firstdoi
A global call from five countries to collaborate in antibiotic stewardship: united we succeed, divided we might fail
The Lancet Infectious Diseases 2016cited by 236position: middledoi
When sepsis persists: a review of MRSA bacteraemia salvage therapy
Journal of Antimicrobial Chemotherapy 2015cited by 71position: firstdoi
Antimicrobial Salvage Therapy for Persistent Staphylococcal Bacteremia Using Daptomycin Plus Ceftaroline
Clinical Therapeutics 2014cited by 181position: middledoi
Avoiding the Perfect Storm: The Biologic and Clinical Case for Reevaluating the 7-Day Expectation for Methicillin-Resistant Staphylococcus aureus Bacteremia Before Switching Therapy
Clinical Infectious Diseases 2014cited by 54position: firstdoi
A multicentre evaluation of the effectiveness and safety of high-dose daptomycin for the treatment of infective endocarditis
Journal of Antimicrobial Chemotherapy 2013cited by 103position: firstdoi
Multicenter Study of High-Dose Daptomycin for Treatment of Enterococcal Infections
Antimicrobial Agents and Chemotherapy 2013cited by 86position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

George Sakoulas · University of California San Diego9 papers (2013–2021) · 4 papers (2019–2021)Debra A. Goff · The Ohio State University4 papers (2013–2023)Michael J. Rybak · Rockefeller University4 papers (2013–2019) · 4 papers (2019–2021)Warren E. Rose · University of Wisconsin–Madison3 papers (2014–2019)Anthony M. Casapao · University of Florida Health3 papers (2013–2014) · 2 papers (2019–2019)Sara E. Cosgrove · University of Baltimore2 papers (2013–2013)Susan L. Davis · Henry Ford Health System2 papers (2013–2013)John Segreti · Rush University Medical Center2 papers (2013–2013)Marcus Zervos · Michigan State University2 papers (2019–2019) · 2 papers (2020–2021)Christopher W. Crank · Rush University Medical Center2 papers (2013–2013)Ellie J. C. Goldstein · IBM Research - Almaden2 papers (2016–2023)Victor Nizet · CNR de la Résistance aux Antibiotiques2 papers (2014–2019) · 2 papers (2019–2019)Khulood Rizvi · The University of Texas Medical Branch at Galveston2 papers (2019–2019)Ellie J. C. Goldstein · University of California System2 papers (2018–2022) · 2 papers (2020–2021)